Zhejiang Jingxin Pharmaceutical Co.,Ltd. (securities code: 002020), founded in 1990, is a listed pharmaceutical company integrating R & D, production and sales. The company follows the business policy of "strengthening the main business of drugs and developing medical devices", adheres to the enterprise core values of "pragmatism, innovation, inclusiveness and win-win", takes "carefully guarding health" as the mission, and is committed to becoming a leader in the field of mental nerves, cardio cerebrovascular in China. Up to now, the company has a registered capital of 905 million yuan and total assets of 6.143 billion yuan. The company has two headquarters in Xinchang and Hangzhou. It has established Shanghai Research Institute in Shanghai Zhangjiang High Tech Park and has eight production bases, including preparation production base in Xinchang, API production base in Shangyu and Shangrao, Jiangxi, traditional Chinese medicine production base in Bayannur, Inner Mongolia and Shaxi, Guangdong, medical device production base in Shenzhen and Shenyang and traditional Chinese medicine raw material base in Yunnan, And invest in the preparation of Shandong base and Beijing Xinchang International Health Industrial Park. Invest and cooperate in the establishment of companies and R & D laboratories in the United States, Israel, South Korea and other countries. The company has more than 3800 employees, including more than 250 doctors. For a long time, adhering to the quality concept of "Beijing new drug, carefully made", the company has fully passed the new version of GMP certification. The production line rate of solid preparation passed the German GMP certification in 2006 and the on-site certification of FDA in 2018. The comprehensive economic benefits of the company have increased rapidly. For many consecutive years, the company has been honored as "excellent enterprise brand for the export of preparations in China's chemical pharmaceutical industry", "top 100 enterprises in China's pharmaceutical industry" and "top 100 enterprises in China's chemical pharmaceutical industry". It is the first batch of "leading enterprises for the internationalization of preparations in China's pharmaceutical enterprises" and the first batch of outstanding units undertaking major scientific and technological special projects of "major new drug creation" in the country, Social popularity and reputation are increasing. The company is a national key high-tech enterprise, with national enterprise technology center, postdoctoral research workstation, provincial key enterprise research institute, provincial academician expert workstation and provincial high-tech enterprise R & D center. It has established Shanghai Research Institute in Shanghai Zhangjiang High Tech Park, and has long cooperated with Shanghai Pharmaceutical Industry Research Institute, Shanghai Institute of organic chemistry, Chinese Academy of Sciences Zhejiang University and other famous scientific research institutes, R & D companies at home and abroad, as well as famous universities, have maintained long-term good exchanges and cooperation, have strong scientific research and technical force, have achieved fruitful results in R & D, have 8 national key new products and undertake 9 National Torch Program projects. As of June 30, 2021, the company has accumulated 173 valid patents, including 121 invention patents (114 domestic invention patents, 4 American invention patents, 1 European invention patent, 1 Japanese invention patent and 1 Korean invention patent), 27 utility models and 25 appearance designs, reflecting the company's strong R & D strength and innovation ability.